9 APR 2024 Pharmaceuticals Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
5 APR 2024 Pharmaceuticals Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry in the U.S.
2 APR 2024 Pharmaceuticals FACEDUO Emotion Recognition Training VR now available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -
2 APR 2024 Pharmaceuticals U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital Therapeutic Authorized in the U.S. for the Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms
29 MAR 2024 Pharmaceuticals Submission of an Application for the First Hematological Malignancies Gene Panel Test in Japan
27 MAR 2024 Pharmaceuticals Abilify Maintena® 960mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia
26 MAR 2024 Pharmaceuticals Novartis receives approval in Japan for Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients with chronic heart failure
22 MAR 2024 Pharmaceuticals Otsuka Pharmaceutical's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis
22 MAR 2024 Pharmaceuticals Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
22 MAR 2024 Pharmaceuticals Otsuka and Lundbeck Presented New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease
21 MAR 2024 Corporate Otsuka Pharmaceutical Enters into Cooperation Agreement on Heat Illness Prevention with Environmental Restoration and Conservation Agency
15 MAR 2024 Pharmaceuticals Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide -
6 MAR 2024 Corporate Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 70.1 KB)
1 MAR 2024 Nutraceuticals New SOYJOY Fig & Raisin A Whole-Soy Nutrition Bar Enhanced with Flavorful Figs
26 FEB 2024 Nutraceuticals Otsuka Sponsors TOKYO MARATHON 2024 POCARI SWEAT Supports Runners Achieve Their Goals
19 FEB 2024 Nutraceuticals Launch of AR-Based Nutrition Education Game App, "Mogumogu Town"Collect "Mogumin" Food Characters and Build Your Town
16 FEB 2024 Pharmaceuticals Sibeprenlimab Received U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy (IgAN)
13 FEB 2024 Corporate Otsuka Pharmaceutical Launches "Kenkokeiei Tsunagaru Support ONLINE"Broadening Support for Resolving Corporate Health Challenges
13 FEB 2024 Pharmaceuticals Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
9 FEB 2024 Pharmaceuticals Novartis Obtains Approval for Additional Indication of Pediatric Chronic Heart Failure for Angiotensin Receptor Neprilysin Inhibitor (ARNI) Entresto® Tablet = Novartis and Otsuka to provide information to healthcare professionals on additional indication for Entresto =
8 FEB 2024 Pharmaceuticals Otsuka and Jolly Good to Start Delivery of FACEDUO Content for Family Support of People with Severe Social Withdrawal (Hikikomori) FACEDUO is a virtual reality program for social skills training support
7 FEB 2024 Corporate Otsuka Group Selected for CDP Climate Change A List for a Second Consecutive Year
31 JAN 2024 Corporate Otsuka Pharmaceutical Installs Solar Power Generation Systems at Tokushima Mima and Other FactoriesAccelerating Carbon Neutrality Initiatives
23 JAN 2024 Corporate Otsuka Pharmaceutical Achieves "Silver" Level Certification as a "Sports Yell Company" from the Japan Sports Agency